Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT03365882 |
TitleS1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery | Phase
Phase 2
|
Date Added 2017-12-07 |
Location
Alaska, United States
Arizona, United States Arkansas, United States California, United States Colorado, United States Connecticut, United States Florida, United States Georgia, United States Hawaii, United States Idaho, United States Illinois, United States Indiana, United States Iowa, United States Kansas, United States Kentucky, United States Louisiana, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Mississippi, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New Hampshire, United States New Jersey, United States New Mexico, United States North Carolina, United States North Dakota, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Rhode Island, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Vermont, United States Washington, United States West Virginia, United States Wisconsin, United States Wyoming, United States Puerto Rico |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
cetuximab, HER-2 testing, Irinotecan Hydrochloride, Pertuzumab, Trastuzumab, Camptosar, Erbitux, Herceptin, Perjeta |
Tags
MSS/ MMRp
|
| NCT ID NCT03657641 |
TitleRegorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer | Phase
Phase 1
|
Date Added 2018-09-05 |
Location
California, United States
Florida, United States |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Pembrolizumab, Regorafenib, Keytruda, Stivarga |
Tags
MSS/ MMRp
|
| NCT ID NCT03296137 |
TitleAdoptive Cell Therapy Across Cancer Diagnoses | Phase
Phase 1/Phase 2
|
Date Added 2017-09-28 |
Location
Denmark
|
Prior IO Allowed Yes |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
Autologous tumor-infiltrating lymphocytes, Cyclophosphamide, Fludara, Ipilimumab, Nivolumab, proleukin, Opdivo, Yervoy |
Tags
MSS/ MMRp
|
| NCT ID NCT03599765 |
TitleSystemic Therapy With or Without Local Consolidative Therapy in Treating Patients With Oligometastatic Solid Tumor | Phase
Phase 2
|
Date Added 2018-07-26 |
Location
Arizona, United States
Arkansas, United States Hawaii, United States Michigan, United States New Jersey, United States Ohio, United States Texas, United States |
Prior IO Allowed Yes |
CRC-directed No |
Status
Active, not recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03568058 |
TitlePersonalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers | Phase
Phase 1
|
Date Added 2018-06-26 |
Location
California, United States
|
Prior IO Allowed Yes |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
Pembrolizumab, personalized vaccine, Keytruda |
Tags
MSS/ MMRp
|
| NCT ID NCT04003792 |
TitleTreatment With Hepatic Arterial Infusion of Oxaliplatin in Combination With Systemic FOLFIRI Chemotherapy and Bevacuzimab in Patients With Liver-only Colorectal Liver Metastases (CRLM): Conversion to Complete Resection in Patients With Initially Inoperable Liver-only CRLM. | Phase
Phase 2
|
Date Added 2019-07-01 |
Location
Israel
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Bevacizumab, FOLFIRI Protocol, oxaliplatin |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT02988960 |
TitleA Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors | Phase
Phase 1
|
Date Added 2016-12-12 |
Location
California, United States
Illinois, United States Massachusetts, United States North Carolina, United States Tennessee, United States Texas, United States Virginia, United States Australia Canada France Japan Korea, Republic of Spain |
Prior IO Allowed Yes |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
ABBV-181, ABBV-927, Opdivo |
Tags
MSS/ MMRp
|
| NCT ID NCT04426669 |
TitleA Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering | Phase
Phase 1, Phase 2
|
Date Added 2020-06-11 |
Location
Minnesota, United States
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Aldesleukin, Cyclophosphamide, Fludarabine, Tumor Infiltrating Lymphocytes (TIL) |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04062721 |
TitleLocal Immunomodulation After Radiofrequency of Unresectable Colorectal Liver Metastases | Phase
Phase 1
|
Date Added 2019-08-20 |
Location
France
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Not yet recruiting
|
Drugs
Chemotherapy, In situ immunotherapy |
Tags
MSS/ MMRp
|
| NCT ID NCT04895709 |
TitleA Study of BMS-986340 as Monotherapy and in Combination With Nivolumab in Participants With Advanced Solid Tumors | Phase
Phase 1, Phase 2
|
Date Added 2021-05-20 |
Location
California, United States
Iowa, United States New Jersey, United States New York, United States Oregon, United States Tennessee, United States Texas, United States Australia Canada Germany Israel Italy Japan Spain |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
BMS-936558-01, BMS-986340 |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
